, and more. But the synthetic biology company does not want to limit itself to ingredients. Ginkgo has expanded their platform into the vast biotherapeutics space, hence Mahdavi’s appointment. Mahdavi comes to Ginkgo with an impressive track record of commercializing novel therapies. Most recently, he served as the VP of Global Open Innovation at Catalent Pharma Solutions and prior to that as the VP of Strategic Innovation at Swiss manufacturer Lonza for almost 14 years.
Ginkgo’s platform is a full-stack solution for therapeutic cell engineering. Their multi-story lab spaces - called “ ” - are Ginkgo’s biological factories equipped with robots and cutting-edge instruments that enable high-throughput cell engineering. This means that Ginkgo can screen hundreds of thousands of cells and molecular compounds to identify the most promising drug candidates that arethe most cost-effective to produce at scale. For example, in their partnership with Aldevron, Ginkgo was able to increase their outputusing cell engineering and biological process improvement.
Ginkgo has already demonstrated initial success with its platform. During the COVID-19 pandemic, Ginkgo created a public health initiative,
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: FOX10Phoenix - 🏆 83. / 68 더 많은 것을 읽으십시오 »